SCHEMBL10322693

SCHEMBL10322693

CCOC(=O)c1cnc(N2CCN(C)CC2)nc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 4/20 0.56
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
ALDH1A1 P00352 6/20 0.51
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 3/20 0.51
MAPT P10636 2/20 0.51
TP53 P04637 1/20 0.51
LMNA P02545 3/20 0.50
MAPK10 P53779 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPK1 P28482 2/20 0.49
USP2 O75604 1/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
HSD17B10 Q99714 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14626136 0.90 MAPT (0.56) PTPN11MEN1KMT2AALDH1A1RAB9A
SCHEMBL31254423 0.89 PTPN11 (0.58) PTPN11MEN1KMT2AALDH1A1RAB9A
SCHEMBL244184 0.86 KDM4E (0.66) PTPN11KMT2AALDH1A1RAB9ASMN1; SMN2
SCHEMBL21477192 0.86 MEN1 (0.53) PTPN11MEN1KMT2AALDH1A1MAPT
SCHEMBL31254411 0.85 PTPN11 (0.52) PTPN11ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL31254412 0.85 LMNA (0.56) PTPN11ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL29046853 0.84 PTPN11 (0.60) PTPN11ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL30503022 0.84 PTPN11 (0.60) PTPN11ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL31254465 0.84 PTPN11 (0.51) PTPN11ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL31254419 0.83 MAPT (0.62) PTPN11MEN1KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US disclosed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US disclosed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184542-A1 PYRIDO PYRIMIDINES TYMS, TYMP, DPYD PTPN11 2012/4885MEN1 1193/4885KMT2A 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.